Salivary visfatin concentrations in patients with chronic periodontitis: An analysis before and after periodontal therapy

Mopidevi, Anudeep; Penmetsa, Gautami S; Dwarkanath, C D; Dubba, Kavyamala; Gadde, Praveen

doi:10.4103/ijdr.ijdr_673_17

Cited by 11 publications

(13 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies have also examined the effects of non‐surgical periodontal therapy on the levels of adipokines. Non‐surgical periodontal therapy reduced the increased levels of salivary visfatin and improved clinical periodontal values (clinical attachment loss and pocket depth) in periodontal patients to levels comparable with those in non‐periodontal controls 121 . In addition, non‐surgical periodontal therapy improved the levels of serum leptin and high‐sensitivity C‐reactive protein in patients with an increased body mass index 122 .…”

Section: Outcomes Of Non‐surgical Periodontal Therapy In Patients Wit...mentioning

confidence: 94%

“…Non-surgical periodontal therapy reduced the increased levels of salivary visfatin and improved clinical periodontal values (clinical attachment loss and pocket depth) in periodontal patients to levels comparable with those in non-periodontal controls. 121 In addition, non-surgical periodontal therapy improved the levels of serum leptin and highsensitivity C-reactive protein in patients with an increased body mass index. 122 Overall, these results emphasize the need for a modified periodontal therapy approach in patients with chronic kidney disease/end-stage kidney disease that will address the biological and behavioral aspects of these patients.…”

Section: Outcome S Of Non -Surg Ic Al Peri Odontal Ther Apy In Patien...mentioning

confidence: 99%

See 1 more Smart Citation

Association between periodontitis and chronic kidney disease

Parsegian

Randall

Curtis

et al. 2022

Periodontology 2000

View full text Add to dashboard Cite

Periodontitis and chronic kidney disease are chronic conditions with high community prevalence across the world. Patients with chronic kidney disease have been noted to have a high burden of periodontitis, and several shared risk factors have been associated with the prevalence and severity of both conditions. However, the precise relationship between the two conditions, and the extent to which each may contribute to the development of the other, remains a matter of debate. The goals of the present work were to: (a) provide the most current and relevant literature overview of the association between periodontitis and chronic kidney disease; (b) explore mechanisms underlying this association; and (c) determine if evidence exists for an independent association between these conditions. We also assessed whether improved oral hygiene and periodontal treatment could reduce the risk of developing chronic kidney disease and, if so, what protocols these strategies involve. Finally, we aimed to reveal gaps in our current knowledge to delineate the directions of future research. Although the exact relationship between these two conditions has not yet been defined, we highlight the importance of the interprofessional interaction between dental practitioners and the nephrology team and the importance of oral health assessment in the management of chronic kidney disease.

show abstract

Section: Outcomes Of Non‐surgical Periodontal Therapy In Patients Wit...mentioning

confidence: 94%

Section: Outcome S Of Non -Surg Ic Al Peri Odontal Ther Apy In Patien...mentioning

confidence: 99%

Association between periodontitis and chronic kidney disease

Parsegian

Randall

Curtis

et al. 2022

Periodontology 2000

View full text Add to dashboard Cite

show abstract

“…In addition, Mopidevi and cols. observed that visfatin levels decreased following periodontitis treatment (13). Because the inclusion of patients with gingivitis would create a bias, we chose to exclude patients diagnosed with gingivitis.…”

Section: Discussionmentioning

confidence: 99%

“…A limited number of studies show a positive correlation between salivary levels of visfatin and other adipokines such as ghrelin and resistin in patients with type 2 diabetes mellitus (12). It was also recently established that levels of adipokines, including visfatin, are positively correlated with inflammatory conditions involving periodontal tissue, such as chronic periodontitis (13,14). In this study, our goal is to identify whether a relationship exist between salivary visfatin levels and OGTT results showing GDM or a lack thereof.…”

Section: Introductionmentioning

confidence: 96%

Measuring visfatin levels in saliva: an alternative approach to gestational diabetes screening

Içli¹,

Bildaci²

2021

Archives of Endocrinology and Metabolism

View full text Add to dashboard Cite

Objective: Oral glucose tolerance testing (OGTT) is the current recommended approach for the diagnosis of gestational diabetes mellitus (GDM). Visfatin is a type of novel adipokine of interest that mostly participates in glucose metabolism and inflammatory processes. We aim to identify a screening technique for GDM using salivary visfatin levels and to establish this technique's value as a screening method compared to OGTT. Materials and methods: This is a cross-sectional case-control study. The cohort was formed from the saliva samples of pregnant patients in their 24 th through 28 th weeks of gestation. Patients were divided into two groups depending on their GDM status. OGTT and visfatin test results were compared and subjected to further analysis to establish a cutoff value for visfatin testing. Results: ELISA results indicated a significant difference between patients with GDM compared to patients without GDM; the values were 18.89 ± 9.59 and 12.44 ± 8.75, respectively (p: 0.007). A cutoff value of 10.5 ng/mL can be used to detect GDM with 78% sensitivity and 51% specificity. Conclusion: Salivary visfatin levels were significantly higher in patients with GDM. The existence of a differential in the concentration of visfatin in saliva can be utilized to develop a new screening method for GDM.

show abstract

“…Visfatin, also known as pre-B-cell colony-enhancing factor (PBEF) and nicotinamide phosphatidyl transferase (Nampt), is a 52 kDa molecule that was first identified as a cytokine involved in B-cell maturation and is highly expressed in bone marrow, liver, and muscle[ 6 , 7 ]. Visfatin is secreted by a variety of cell types, including lymphocytes, neutrophils, macrophages, and epithelial cells [ 8 ], and is closely associated with various types of inflammatory diseases, including psoriasis [ 9 ], atherosclerosis [ 10 ] and acute lung injury [ 11 ], as well as sepsis [ 12 ].…”

Section: Introductionmentioning

confidence: 99%

Inhibition of visfatin alleviates sepsis-induced intestinal damage by inhibiting Hippo signaling pathway

et al. 2022

View full text Add to dashboard Cite

Background The aim of this study is to investigate role of Visfatin, one of the pro-inflammatory adipokines, in sepsis-induced intestinal injury and to clarify the potential mechanism. Methods C57BL/6 mice underwent cecal ligation and puncture (CLP) surgery to establish sepsis model in vivo. Intestinal epithelial cells were stimulated with LPS to mimic sepsis-induced intestinal injury in vitro. FK866 (the inhibitor of Visfatin) with or without XMU-MP-1 (the inhibitor of Hippo signaling) was applied for treatment. The expression levels of Visfatin, NF-κB and Hippo signaling pathways-related proteins were detected by western blot or immunohistochemistry. The intestinal cell apoptosis and intestinal injury were investigated by TUNEL staining and H&E staining, respectively. ELISA was used to determine the production of inflammatory cytokines. Results The expression of Visfatin increased in CLP mice. FK866 reduced intestinal pathological injury, inflammatory cytokines production, and intestinal cell apoptosis in sepsis mice. Meanwhile, FK866 affected NF-κB and Hippo signaling pathways. Additionally, the effects of FK866 on inflammatory response, apoptosis, Hippo signaling and NF-κB signaling were partly abolished by XMU-MP-1, the inhibitor of Hippo signaling. In vitro experiments also revealed that FK866 exhibited a protective role against LPS-induced inflammatory response and apoptosis in intestinal cells, as well as regulating NF-κB and Hippo signaling, whereas addition of XMU-MP-1 weakened the protective effects of FK866. Conclusion In short, this study demonstrated that inhibition of Visfatin might alleviate sepsis-induced intestinal injury through Hippo signaling pathway, supporting a further research on Visfatin as a therapeutic target.

show abstract

Salivary visfatin concentrations in patients with chronic periodontitis: An analysis before and after periodontal therapy

Cited by 11 publications

References 2 publications

Association between periodontitis and chronic kidney disease

Association between periodontitis and chronic kidney disease

Measuring visfatin levels in saliva: an alternative approach to gestational diabetes screening

Inhibition of visfatin alleviates sepsis-induced intestinal damage by inhibiting Hippo signaling pathway

Contact Info

Product

Resources

About